Literature DB >> 29759692

Impact of Implantable Cardioverter-Defibrillators on Waitlist Mortality Among Patients Awaiting Heart Transplantation: An UNOS/OPTN Analysis.

Kairav Vakil1, Sue Duval2, Rebecca Cogswell2, Peter Eckman3, Wayne C Levy4, Inderjit Anand5, Todd Dardas4, Selcuk Adabag5.   

Abstract

OBJECTIVES: This study sought to assess the impact of implantable cardioverter-defibrillators (ICDs) on waitlist mortality in patients listed for heart transplantation (HT).
BACKGROUND: The impact of ICDs on preventing sudden cardiac death in patients awaiting HT has not been studied in large multicenter cohorts. Furthermore, whether ICDs benefit patients with a left ventricular assist device (LVAD) is unknown.
METHODS: Adults (age ≥18 years) listed for first-time HT in the United States between January 1, 1999, and September 30, 2014, were retrospectively identified from the United Network for Organ Sharing registry. The primary predictor variable was the presence of an ICD at the time of listing. Primary outcome variable was all-cause waitlist mortality.
RESULTS: Data on 32,599 patients (mean age 53 ± 12 years, 77% male, 70% Caucasian) were analyzed. During median follow-up of 154 days, 3,638 patients (11%) died on the waitlist (9% in ICD group vs. 15% in no-ICD group; p < 0.0001), whereas 63% underwent HT. Having an ICD at listing was associated with an adjusted 13% relative reduction in mortality (hazard ratio: 0.87; 95% confidence interval: 0.80 to 0.94). In the subgroup of patients with LVAD (n = 9,478), having an ICD was associated with an adjusted 19% relative reduction in mortality (hazard ratio: 0.81; 95% confidence interval: 0.70 to 0.94).
CONCLUSIONS: ICD use was associated with improved survival on the HT waitlist in patients with or without LVADs. These findings strengthen the current guideline recommendations of using ICDs in nonhospitalized patients awaiting HT and provide new insight into the effectiveness of ICDs on survival in LVAD-supported patients.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  heart transplantation; implantable cardioverter-defibrillator; left ventricular assist device; mortality; waitlist

Mesh:

Year:  2016        PMID: 29759692     DOI: 10.1016/j.jacep.2016.07.010

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  5 in total

1.  ICD shocks in LVAD patients are not associated with increased subsequent mortality risk.

Authors:  Aswini Kumar; Varun Tandon; David M O'Sullivan; Edmond Cronin; Jason Gluck; Jeffrey Kluger
Journal:  J Interv Card Electrophysiol       Date:  2019-09-10       Impact factor: 1.900

2.  Implantable Cardioverter-Defibrillators in Patients With a Continuous-Flow Left Ventricular Assist Device: An Analysis of the INTERMACS Registry.

Authors:  Kevin J Clerkin; Veli K Topkara; Ryan T Demmer; Jose M Dizon; Melana Yuzefpolskaya; Justin A Fried; Xingchen Mai; Donna M Mancini; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Paolo C Colombo; A Reshad Garan
Journal:  JACC Heart Fail       Date:  2017-12       Impact factor: 12.035

3.  Change in indication for cardiac resynchronization therapy?

Authors:  Dennis Lawin; Christoph Stellbrink
Journal:  Eur J Cardiothorac Surg       Date:  2019-06-01       Impact factor: 4.191

4.  Implantable Cardioverter Defibrillators in Patients With Continuous Flow Left Ventricular Assist Devices: Utilization Patterns, Related Procedures, and Complications.

Authors:  Paulino A Alvarez; Brett W Sperry; Antonio L Pérez; Dmitry M Yaranov; Varinder Randhawa; Jacob Luthman; Daniel J Cantillon; Randall C Starling
Journal:  J Am Heart Assoc       Date:  2019-07-06       Impact factor: 5.501

5.  Association between implantable cardioverter-defibrillator and survival in patients awaiting heart transplantation: A meta-analysis and systematic review.

Authors:  Andrew Y Lin; Jason M Duran; Alexandra Sykes; Douglas Darden; Marcus Urey; Jonathan C Hsu; Eric D Adler; Ulrika Birgersdotter-Green
Journal:  Heart Rhythm O2       Date:  2021-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.